Risperidone could induce hyperprolactinemia in excessive dopamine receptor blockade (Oda et al., 2015) due to its high dopamine D2 receptor occupancy (68–70%) (Tsuboi et al., 2013), resulting in hyperprolactinemia in early treatment. The gene discussed is DRD2; the disease is hyperprolactinemia.